Palleon Pharmaceuticals Overview
- Founded
-
2015
- Status
-
Private
- Employees
-
42
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$100M
- Investors
-
8
Palleon Pharmaceuticals General Information
Description
Developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer. The company's biotechnology platform integrates technologies and insights from scientific leaders all over the world in the fields of glycoscience and human immunology to create a novel approach to treat cancer by targeting multiple immune cell types, providing physicians with a wider range of rational combination therapies to treat cancer and tackle resistance to first-generation immuno-oncology agents.
Contact Information
Website
www.palleonpharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- 266 2nd Avenue
- Waltham, MA 02451
- United States
+1 (857) 000-0000
Palleon Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 16-Sep-2020 | $100M | 00000 | 00000 | Completed | Clinical Trials - Phase 1 |
| 2. Early Stage VC (Series A) | 04-Oct-2017 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 1. Accelerator/Incubator | Completed | Clinical Trials - Phase 1 |
Palleon Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 00.000 |
| Series A | 00,000,000 | 00.000000 | 00.00 | 00 | 00 | 00 | 00 | 00.000 |
Palleon Pharmaceuticals Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer. The company's
Drug Discovery
Waltham, MA
42
As of 2022
00000
0000
0000-00-00
00000000000
00000
000000
voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non
0000000000000
Gaithersburg, MD
00
As of 0000
00000
0000
0000-00-00
00000000
00000
000000
oris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate ve
0000 000000000
San Diego, CA
000
As of 0000
00000
000000000
00000
Add Comparison
Palleon Pharmaceuticals Competitors (14)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| 000000000 00000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
| 000000 00000000000 | Formerly VC-backed | Burlingame, CA | 00 | 00000 | 000000 - 000 | 00000 |
| 000000000 | Venture Capital-Backed | Berlin, Germany | 00 | 00000 | 0000000000 0 | 00000 |
| 0000000 | Venture Capital-Backed | Berlin, Germany | 0 | 00.000 | 000000000 | 00.000 |
Palleon Pharmaceuticals Patents
Palleon Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020298628-A1 | Sialidase-cd20-antibody fusion proteins and methods of use thereof | Pending | 03-Jul-2019 | 00000000000 | |
| CA-3145672-A1 | Sialidase-cd20-antibody fusion proteins and methods of use thereof | Pending | 03-Jul-2019 | 00000000000 | |
| EP-3994179-A1 | Sialidase-cd20-antibody fusion proteins and methods of use thereof | Pending | 03-Jul-2019 | 00000000000 | |
| AU-2020300680-A1 | Recombinant sialidases and methods of using the same | Pending | 03-Jul-2019 | 00000000000 | |
| CA-3145772-A1 | Recombinant sialidases and methods of using the same | Pending | 03-Jul-2019 | A61K47/6815 |
Palleon Pharmaceuticals Executive Team (7)
Palleon Pharmaceuticals Board Members (19)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alan Colowick MD | Matrix Capital Management | Board Member | 000 0000 |
| David Johnson | Self | Board Member | 000 0000 |
| Deepa Pakianathan Ph.D | Palleon Pharmaceuticals | Board Member | 000 0000 |
| Denis Patrick Ph.D | Self | Board Member | 000 0000 |
| James Broderick MD | Palleon Pharmaceuticals | Co-Founder, Chief Executive Officer, President & Board Member | 000 0000 |
Palleon Pharmaceuticals Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Palleon Pharmaceuticals Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Citadel Enterprise Americas | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Matrix Capital Management | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| Surveyor Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
| AbbVie Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Pfizer Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |